Tailored priming of pancreatic cancer progression and metastatic targeting using KD025, a phase II (ROCK2) inhibitor: fine-tuning treatment via single cell intravital imaging
GA ID:
Agency:
National Health and Medical Research Council (NHMRC)
Publish Date:
21-Dec-2018
Category:
Medical Research
Grant Term:
1-Jan-2019
to
31-Dec-2022
Value (AUD):
$892,362.00
Recipient Name:
Garvan Institute of Medical Research
Last Updated:
21-Dec-2018 9:52 am (ACT Local Time)